Relay Therapeutics (RLAY) Total Liabilities (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Total Liabilities data on file, last reported at $57.4 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 26.64% year-over-year to $57.4 million in Q1 2026; TTM through Mar 2026 was $57.4 million, a 26.64% decrease from a year earlier, with the FY2025 full-year figure at $54.3 million, down 41.96% from the prior year.
• Total Liabilities for Q1 2026 stood at $57.4 million, up from $54.3 million in the prior quarter.
• Over the last five years, Total Liabilities for RLAY reached as high as $168.9 million in Q3 2022 and fell as low as $54.3 million in Q4 2025.
• Historically, Total Liabilities has averaged $102.9 million across 5 years, with a median of $93.5 million in 2024.
• Across the five-year window, Total Liabilities surged 179.84% in 2022 and plunged 41.96% in 2025, its largest moves.
• Year by year, Total Liabilities stood at $149.6 million in 2022, then slumped by 38.5% to $92.0 million in 2023, then increased by 1.66% to $93.5 million in 2024, then plunged by 41.96% to $54.3 million in 2025, then increased by 5.82% to $57.4 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $57.4 million in Q1 2026, $54.3 million in Q4 2025, and $62.3 million in Q3 2025.